 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | CKD-504 / Chong Kun Dang
Journal: HDAC6 Inhibition Corrects Electrophysiological and Axonal Transport Deficits in a Human Stem Cell-Based Model of Charcot-Marie-Tooth Disease (Type 2D). (Pubmed Central) - May 6, 2022
Treatment with histone deacetylase 6 inhibitors, tubastatin A and CKD504, improves mitochondrial movement and α-tubulin acetylation in these cells. Furthermore, CKD504 treatment enhances population-level electrophysiological activity, highlighting its potential as an effective treatment for CMT2D.
- | CKD-504 / Chong Kun Dang
Journal, Epigenetic controller: Therapeutic Potential of CKD-504, a Novel Selective Histone Deacetylase 6 Inhibitor, in a Zebrafish Model of Neuromuscular Junction Disorders. (Pubmed Central) - Apr 9, 2022
In the present study, we demonstrated that HDAC6 inhibition was sufficient to enhance movement by restoring NMJ impairments observed in a zebrafish disease model. We found that CKD-504, a novel HDAC6 inhibitor, was effective in repairing NMJ defects, suggesting that treatment of neurodegenerative diseases via NMJ targeting is possible.
- | CKD-504 / Chong Kun Dang
Journal, Epigenetic controller: A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A. (Pubmed Central) - Jun 22, 2021
We found that CKD-504, a novel HDAC6 inhibitor, was effective in repairing NMJ defects, suggesting that treatment of neurodegenerative diseases via NMJ targeting is possible. A novel HDAC6 inhibitor, CKD-504, has potent therapeutic efficacy for CMT1A.
- | CKD-504 / Chong Kun Dang
Preclinical, Journal: Acetylation changes tau interactome to degrade tau in Alzheimer's disease animal and organoid models. (Pubmed Central) - Jan 15, 2021
We found a histone deacetylase 6 (HDAC6) inhibitor, CKD-504, changed the tau interactome dramatically to degrade pathological tau not only in AD animal model (ADLP ) brains containing both amyloid plaques and neurofibrillary tangles but also in AD patient-derived brain organoids...We also identified the responsible acetylation sites on tau. These dramatic tau-interactome changes may result in tau degradation, leading to the recovery of synaptic pathology and cognitive decline in the ADLP mice.
- || CKD-504 / Chong Kun Dang
Trial completion date, Trial primary completion date: CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects (clinicaltrials.gov) - Feb 7, 2020
P1, N=88, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
These dramatic tau-interactome changes may result in tau degradation, leading to the recovery of synaptic pathology and cognitive decline in the ADLP mice. Trial completion date: Feb 2020 --> Dec 2020 | Trial primary completion date: Nov 2019 --> Dec 2020
- | CKD-504 / Chong Kun Dang
New P1 trial: CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects (clinicaltrials.gov) - Oct 22, 2018
P1, N=88, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical